Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): AST2303 tablets receive approval for drug clinical trials.
Ails (688578.SH) announced recently that the company has received the approval and issuance of the "Drug Clinical ..." by the National Medical Products Administration.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the clinical trial of AST2303 tablets in adult patients with advanced non-small cell lung cancer carrying the EGFR C797S mutation. The announcement states that AST2303 tablets (ABK3376 tablets) are a highly selective and brain-permeable new generation EGFR oral small molecule inhibitor that can effectively inhibit the EGFRC797S mutation.
Related Articles
SOUTH MANGANESE (01091) released its annual performance, with a net profit attributable to shareholders of 167 million Hong Kong dollars, turning from a loss to a profit year-on-year.
China Merchants Bank (03968) plans to fully redeem "CMB Wealth 1" on April 15th.
Uni-Trend Technology (688628.SH) plans to acquire 51% of the shares of XinCe Communication for no more than 86 million yuan.
SOUTH MANGANESE (01091) released its annual performance, with a net profit attributable to shareholders of 167 million Hong Kong dollars, turning from a loss to a profit year-on-year.
China Merchants Bank (03968) plans to fully redeem "CMB Wealth 1" on April 15th.
Uni-Trend Technology (688628.SH) plans to acquire 51% of the shares of XinCe Communication for no more than 86 million yuan.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
